International Desk: A new study by the World Health Organization (WHO) has revealed that covid patients with the use of antiviral drug remedicivir have very little or no chance of surviving for a relatively long time. The WHO evaluated trials of four possible drugs of Covid-19, including remedicivir and hydroxychloroquine, according to the WHO.

remedicivir is one of the first drugs used to treat coronavirus. Remedies were also used to treat US President Donald Trump while he was hospitalized with the coronavirus. The manufacturer of the drug, Gilead Sciences, however, has rejected the claim of the World Health Organization. Gilead said in a statement that the data from the study were "inconsistent" with other studies and that they were concerned about whether the results of the recent study had been re-evaluated.

For solidarity clinical trials, the WHO tested four potential drugs for efficacy. These included a combination of the Ebola drug Remdesivir, the malaria drug hydroxychloroquine, the autoimmune drug interferon, and the lopinavir and ritonavir used as HIV drugs. Dexamethasone, a low-cost steroid used in patients with coronavirus in the UK ICU, was not included in the study. Four drug tests were performed on 11,026 adult patients in a total of 500 hospitals in more than 30 countries.

A peer review of the results of that study or a comparative review with research on similar topics has not yet been completed. However, the World Health Organization says there is not enough evidence so far that any of these four drugs have a role in preventing Kovid-19 deaths or affecting hospital stays.

The trials of hydroxychloroquine and lopinavir / ritonavir were halted last June, said Soumya Swaminathan, chief scientist at the World Health Organization. Because, at that time, it is proved that those drugs are ineffective. However, trials of other drugs were going on. The results of a recent study conducted by the World Health Organization contradict the results of a study conducted by Gilead earlier this month. The Gilead study found that the use of remediation in covid-19 patients in intensive care units could reduce hospital stay by five days. About one thousand Kovid-19 patients took part in the trial.

Ref: BBC